of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (DART)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00925717
First received: June 19, 2009
Last updated: January 25, 2010
Last verified: January 2010
  Purpose

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.


Condition
Low Density Lipoprotein Cholesterol Goal Achievement

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Investigate LDL-C goal achievement rate according to ADA recommendation [ Time Frame: Within the last 6 months from the date of data entry. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Investigate reduction of 10-year risk for CHD by using UKPDS risk engine [ Time Frame: Within the last 6 months from the date of data entry. ] [ Designated as safety issue: No ]

Enrollment: 4045
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
2500 patients
Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

Criteria

Inclusion Criteria:

  • Subjects who was diagnosed as diabetes
  • Subjects who was diagnosed as dyslipidaemia or takes lipid lowering medication
  • Clinic visit in the past 6 months more than once

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00925717

Locations
Korea, Republic of
Research Site
Cheonan-si, Chungchungnam-do, Korea, Republic of
Research Site
Ansan-si, Gyeonggi-do, Korea, Republic of
Research Site
Anyang-si, Gyeonggi-do, Korea, Republic of
Research Site
Bucheon-si, Gyeonggi-do, Korea, Republic of
Research Site
Goyang-si, Gyeonggi-do, Korea, Republic of
Research Site
Seongnam-si, Gyeonggi-do, Korea, Republic of
Research Site
Suwon-si, Gyeonggi-do, Korea, Republic of
Research Site
Uijeongbu-si, Gyeonggi-do, Korea, Republic of
Research Site
Gwangju-si, Jeollanam-do, Korea, Republic of
Research Site
Suncheon, Jeollanam-do, Korea, Republic of
Research Site
Jeonju-si, Jeonllabuk-do, Korea, Republic of
Research Site
Chuncheon, Kangwon-do, Korea, Republic of
Research Site
Chuncheon-si, Kangwon-do, Korea, Republic of
Research Site
Kang-Neung, Kangwon-do, Korea, Republic of
Research Site
Wonju-si, Kangwon-do, Korea, Republic of
Research Site
Busan-si, Korea, Republic of
Research Site
Cheonju-si, Korea, Republic of
Research Site
Daegu-si, Korea, Republic of
Research Site
Daejeon-si, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Incheon-si, Korea, Republic of
Research Site
Jeonju-si, Korea, Republic of
Research Site
Kwangju-si, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: MoonGyu Lee, Ph.D. Samsung Medical Center
  More Information

No publications provided

Responsible Party: Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00925717     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/1
Study First Received: June 19, 2009
Last Updated: January 25, 2010
Health Authority: Korea: N/A

Keywords provided by AstraZeneca:
ADA recommendation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 22, 2014